Astellas Pharma Inc: Carcinoma trials

The registry lists 10 Carcinoma studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 4Phase 2 3Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaCompletedNCT02639182Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular CarcinomaCompletedNCT02528643Phase 2Results posted
• An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial CarcinomaApproved for marketingNCT04136808
• A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT03070990Phase 1
• An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian FederationCompletedNCT02128334
• A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary HistologyCompletedNCT01672775Phase 1
• A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney CancerCompletedNCT01114230Phase 1
• A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCCTerminatedNCT01101906Phase 2
• A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical CarcinomaCompletedNCT00924989Phase 3
• A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell CancerTerminatedNCT00816686Phase 1